The Fight Between Pharma and CMS Over Drug Pricing Reform Has Only Just Begun

Despite efforts by the pharma industry to stop it, Medicare prescription drug pricing negotiations from the US Inflation Reduction act still loom on the horizon. As a result, the industry is shifting its approach, now focusing on changing the law to its favor. Although pharma is putting energy into lobbying, litigation is soon to come.

According to Marc Iskowitz, “If the big trade group does mount a lawsuit, it’s likely to pounce on a number of areas of the proposed negotiation, spelled out in a 76-page document filed with regulators last week. The letter follows industry’s previously voiced concerns about the law’s unintended R&D consequences, which drugmakers have been talking about in earnings calls and investor presentations over the seven months since the IRA’s passage.”

To read more, click here.

(Source: MM+M, April 24^th, 2023)